Özdemir, Sefayi Merve

Profile URL
https://hdl.handle.net/11147/16008
Name Variants
Job Title
Email Address
Main Affiliation
01. Izmir Institute of Technology
Status
External
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

SDG data is not available
This researcher does not have a Scopus ID.
This researcher does not have a WoS ID.
No records found in other affiliations.
Scholarly Output

1

Articles

0

Views / Downloads

948/406

Supervised MSc Theses

1

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

0

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.00

Open Access Source

1

Supervised Theses

1

Journals data is not available

Scopus Quartile Distribution

Quartile distribution chart data is not available

Competency Cloud

GCRIS Competency Cloud

Filters

20211

Settings

Author of Publication: search.filters.isAuthorOfPublication.553ab217-7b2f-4c24-8967-ed79bdc342c5

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Master Thesis
    Investigation of Anticancer Properties of Novel Mdm2 Inhibitors
    (Izmir Institute of Technology, 2021) Özdemir, Sefayi Merve; Çağır, Ali; Çağır, Ali; 01. Izmir Institute of Technology; 04.01. Department of Chemistry; 04. Faculty of Science
    Cancer is one major disease causing death worldwide. Current cancer treatments are not %100 effective to cure for patients, yet. Thereby, the synthesis and discovery of new therapeutics have been important to improve the survival period of the cancer patients. There are many strategies for synthesis of cancer therapeutics. One of the most important strategy for cancer treatment is the reactivation of p53. MDM2 is a negative regulator of p53 in cell, because it causes the inactivation of p53. In this thesis, the anticancer and MDM2 inhibitory properties of ezetimibe, desfluoro ezetimibe and intermediates during ezetimibe synthesis (named as SM2-9) and a side product from the synthesis of benidipine (named as SM1) on prostate cancer (LnCAP, wild-type p53), breast cancer (MCF7, wild type p53) and uterus cancer (HeLa, wild type nonfunctional p53) cells were investigated. For this purpose, the cytotoxic, cytostatic and apoptotic properties of these compounds were determined. Compounds SM2, SM3, SM4 and SM6 demonstrated cytotoxic effects, whereas compounds SM5, SM8 and SM9 had cytostatic effects on three cells. Compound SM7 had no effect on these cells, up to 100 μM concentration. Compounds SM1 had cytostatic effect on MCF7 cells, but it showed no activity on other cells. Compounds SM8 and SM9 had strong cytostatic activity. Thus, the apoptotic properties of these compounds were examined by caspases 3/7 activation and Annexin-V FITC assays. Besides, MDM2 inhibitor profiles of these compounds were investigated by fluorescence polarization assay. This study provides novel and potential molecules for drug discovery in cancer treatment